Vitrolife

Excellence in reproductive health Today, we support customers worldwide - always with sustainability in mind. We are your committed partner for the IVF journey.

Vitrolife is committed to supporting successful treatment outcomes and has been dedicated to IVF since 1994, when the field was still young. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for fertility clinics, founded in 2011. Together we create Vitrolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genet

ic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 32 countries, and a network of distributors. Our vision is to enable people to fulfil the dream of having a healthy baby), and we achieve this by supporting our customers in delivering successful treatment outcomes. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. Together we create excellence in reproductive health. We can help you maximise success. – Together. All the way. The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.

30/04/2026

Vitrolife Group is proud to participate in the ASPIRE 2026 Congress in Beijing, taking place 7–10 May 2026.

Join us on 8 May for our symposium, where Prof. Cecilia Sjoblom and leading international speakers will share the latest insights to help you improve outcomes for patients of advanced maternal age.

Looking forward to welcoming you in Beijing!

28/04/2026

“Both the EmbryoScope and PGT-A Plus have allowed Terra Fertility to deliver on its promise of transparency and the best care for patients as they go through a fertility journey.”

– Denis Vaughan, MD | Boston, MA.

See how Terra Fertility is elevating care and supporting outcomes with our innovative technologies.

💡EmbryoScope and PGT-A Plus provide two powerful pieces of information for clinics.
💡 For fringe cases where patients have fewer embryos to choose from, PGT-A Plus may increase the number of embryos for transfer consideration.
💡PGT-A Plus improves accuracy and confidence in the PGT-A test.
💡The additional data from both technologies improve transparency and reduce anxiety for patients.

Learn more here:
https://www.vitrolife.com/our-products/explore-all-the-benefits/?utm_source=Social%20Media&utm_medium=Social%20Media&utm_campaign=Social%20Media #24458

24/04/2026

💡 We’re excited to share the article: “Can cell-free DNA in the culture medium predict the chromosomal constitution of preimplantation embryos? Final results from a multicenter study with 2539 blastocysts”

Our latest research paper further supports the use of non-invasive PGT-A to effectively assess embryo aneuploidy and its potential as a prioritisation tool for embryo selection.

💡This study - performed with the highest sample size analysed to date - confirms that the embryo culture protocol used is robust across different laboratories, without affecting embryo viability and developmental potential.

💡High culture medium informativity and concordance rates have been obtained with the corresponding trophectoderm and inner cell mass.

💡Analysis of the embryo transfers performed (n=265) revealed a trend towards lower miscarriage rate in blastocysts where both trophectoderm and medium were euploid, compared to those with a euploid trophectoderm and an aneuploid medium.

💡This approach could be especially useful for patients with no PGT-A indications, those with vitrified embryos that have had unsuccessful previous transfers, and intended parents who do not wish to biopsy their embryos or do not have access to invasive PGT-A due to legal or geographical restrictions.

The study is conducted in collaboration with Carmen Rubio, Emilio de la Fuente Lucena, Luis Navarro Sánchez, Denny Sakkas, Nilo Frantz, Bill Venier, Daria Maria Soscia, Gerardo Barroso, Claudio Bisioli, Michael DiMattina, Bilgen Teke and Luis Ernesto Escudero.

You find the full article here:
👉 https://www.mdpi.com/3821408

-A

23/04/2026

Vitrolife Group has published its Q1 2026 report today.

A good start to the year with 5% organic growth in local currencies, building on solid momentum and proactively navigating dynamic market conditions, while maintaining a clear focus on executing our long-term strategy.

Highlights:
- Americas sales +11% organic growth in local currencies: Accelerating growth in Consumables and Technologies in North America.
- Gross Margin 59.9%: One of the strongest quarters in terms of gross margin performance.
- Consumables +9% organic growth in local currencies: Strong organic growth across Consumables portfolio in key markets.

- Bronwyn Brophy O'Connor, CEO

21/04/2026

ALPHA 2026 brought together leading minds from across the field of reproductive medicine, creating a dynamic space for knowledge exchange, discussion, and new perspectives. The event served as a powerful platform to connect science with real-world experience, fostering meaningful dialogue and fresh ideas.

Thanks to everyone who joined us!

20/04/2026

This week, we recognize National Infertility Awareness Week 🧡 A movement founded by RESOLVE: The National Infertility Association to raise awareness, foster education, and support those facing infertility.

1 in 6 couples experience infertility, a reality that fuels our purpose at Vitrolife Group: to help people fulfill their dream of having a healthy baby. Our passion and commitment to advancing reproductive care have never been stronger, and our hearts are with everyone on this journey.

16/04/2026

We’re excited to share that Vitrolife Group will be attending the 23rd PGDIS Conference in Shanghai, China, from April 24–27.

Visit us at booth C5 to discover our latest solutions, designed to support the unique needs of your lab or clinic. It’s a great opportunity to connect with our team and explore how we can contribute to your lab or clinic’s ongoing needs.

Looking forward to seeing you in Shanghai!

09/04/2026

We’re heading to ALPHA Conference 2026 in Dubrovnik, 17–19 April!

Make sure to stop by our booth and connect with our team. Here’s what you can expect:

💡Live demos of our cutting-edge AI embryo evaluation: iDAScore & KIDScore
💡Exclusive updates on our latest publications, innovations, and services
💡Quality insights - join our interactive quiz and test your knowledge
💡Hands-on demonstrations of the vitrification process
💡Private conversations with our genetics experts, tailored to your clinic’s needs

Interested in learning more or booking a private session with one of our specialists? Send us a DM or leave a comment, and we’ll make sure you connect with the right expert.

We hope to see you there! 🤍

26/03/2026

We are pleased to announce the release of Vitrolife Group’s Annual Report for 2025.

Despite a volatile market, we delivered a resilient performance, continued to gain market share in key regions, and maintained our strategic focus on growth, innovation, and operational excellence. Our underlying business remains robust and well-balanced, supported by recurring customers, strong satisfaction scores, and our commitment to education and training that empowers our clients to deliver the best possible patient outcomes.

Looking ahead, we remain confident in our ability to drive sustainable, profitable growth and deliver on our mission: striving for better treatment outcomes for patients and helping more families fulfil the dream of a healthy baby.

Thanks to all our dedicated colleagues, valued customers, and committed shareholders for your trust and partnership.

Read the full report here: https://ow.ly/r0GT50Yz0pq

19/03/2026

Order online – simple, fast, and always available.

Did you know you can save time by placing your order online in our webshop? If you don’t already have an online account and want to place orders online, track your orders, access CoAs, view invoices, review previous orders, and much more, you can request an account today. It’s quick and easy!

Click here to request an account:
👉 https://ow.ly/jVnO50Ywm8z

13/03/2026

💡Protecting embryos from oxidative stress starts with the right media solution.

Three antioxidants have been added to our gamete-handling, fertilisation, and culture media to form a protective barrier against oxidative stress. Together, they are integrated in Gx Media, supporting all stages of the process. For optimal results, use the complete system.

Read more here:
👉 https://ow.ly/XTQa50Yti5G

Adress

Gustaf Werners Gata 2
Västra Frölunda
42132

Webbplats

https://www.vitrolife.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när Vitrolife postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Vill du placera din praktik längst upp i Klinik-listan i Västra Frölunda?

Dela

Typ

Leverantör av medicinsk utrustning

Together. All the way.

Vitrolife was established in Sweden in 1994 when the field of assisted reproduction was still young. The possibility to help people become parents through assisted reproduction became a reality in the 1960s, following the development of a method for fertilising eggs outside the body. The birth of Louise Brown in 1978 – the first baby born as a result of in vitro fertilisation (IVF) – gave new hope to men and women suffering from infertility. As IVF techniques developed, the importance of individual components on IVF success began to be understood. The founders of Vitrolife realised the value of using culture media with consistent and repeatable performance; the manufacturing and delivering of LOTto-LOT consistency they developed is still significant for Vitrolife today. Through well-executed product development, consistent quality controls and the acquisition of other innovative IVF companies, Vitrolife has grown with the market globally. As a result, Vitrolife provides an unbroken chain of quality products, securing results at every step of IVF treatment. Only Vitrolife can guarantee every link in this chain. Our commitment to increase pregnancy rates has never been more dedicated. Together with equally devoted clinics, we are improving IVF success and fulfilling more couples’ greatest dream. We are very proud to be a part of making this happen.